Status:
UNKNOWN
A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar Depression.
Lead Sponsor:
Sheba Medical Center
Collaborating Sponsors:
Jerusalem Mental Health Center
Conditions:
Bipolar Disorder
Major Depressive Disorder
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
We hypothesize that depressed patients who have not responded to their current antidepressant medication will respond to the addition of ropinirole to their current regimen at a rate better than place...
Detailed Description
Most pharmacologic treatments of depression rely on serotonergic and/or noradrenergic mechanisms. Yet, evidence both from animal studies and from human trials suggests a role for dopaminergic pathways...
Eligibility Criteria
Inclusion
- DSM-IV Major Depression OR Bipolar I or II Disorder - Currently Depressed
- One month of a stable, adequate dose of antidepressant medication
- Bipolar patients must have a mood stabilizer
- At least 18 years old
- Modified HDRS-21 more than 16 (Scores reverse vegetative symptoms.)
- Informed Consent
Exclusion
- CVA
- Antipsychotic Medication
- Drug or Alcohol Abuse
- Active Suicidality
- Rapid Cycling Bipolar Disorder
- Neurologic or Dementing Illness
- Psychosis
- Parkinsonism
- Pregnancy
Key Trial Info
Start Date :
April 1 2003
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00335205
Start Date
April 1 2003
Last Update
June 9 2006
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Jerusalem Mental Health Center
Jerusalem, Israel
2
Chaim Sheba Medical Center, Dept. of Psychiatry
Tel Litwinsky, Israel, 52621